Journal article
Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression
R Stuchbery, G Macintyre, M Cmero, LM Harewood, JS Peters, AJ Costello, CM Hovens, NM Corcoran
Oncotarget | IMPACT JOURNALS LLC | Published : 2016
Abstract
Background: Despite the importance of androgen receptor (AR) signalling to prostate cancer development, little is known about how this signalling pathway changes with increasing grade and stage of the disease. Objective: To explore changes in the normal AR transcriptome in localised prostate cancer, and its relation to adverse pathological features and disease recurrence. Design: Publically accessible human prostate cancer expression arrays as well as RNA sequencing data from the prostate TCGA. Tumour associated PSA and PSAD were calculated for a large cohort of men (n=1108) undergoing prostatectomy. Outcome Measurements and Statistical Analysis: We performed a meta-analysis of the expressio..
View full abstractGrants
Awarded by NHMRC
Funding Acknowledgements
This work is supported by a project grant from the NHMRC, ID: 1024081. The Australian Prostate Cancer Centre Epworth is supported by the Australian Government as represented by the Department of Health and Ageing. N.M.C. is supported by a David Bickart Clinician Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.